These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 35179707)

  • 1. VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications.
    Camarda N; Travers R; Yang VK; London C; Jaffe IZ
    Curr Oncol Rep; 2022 Apr; 24(4):463-474. PubMed ID: 35179707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension.
    Versmissen J; Mirabito Colafella KM; Koolen SLW; Danser AHJ
    Cardiovasc Res; 2019 Apr; 115(5):904-914. PubMed ID: 30726882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association.
    Cohen JB; Brown NJ; Brown SA; Dent S; van Dorst DCH; Herrmann SM; Lang NN; Oudit GY; Touyz RM;
    Hypertension; 2023 Mar; 80(3):e46-e57. PubMed ID: 36621810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress.
    Lankhorst S; Kappers MH; van Esch JH; Danser AH; van den Meiracker AH
    Antioxid Redox Signal; 2014 Jan; 20(1):135-45. PubMed ID: 23458507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelin-1 and antiangiogenesis.
    Lankhorst S; Danser AH; van den Meiracker AH
    Am J Physiol Regul Integr Comp Physiol; 2016 Feb; 310(3):R230-4. PubMed ID: 26511523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
    Kruzliak P; Novák J; Novák M
    Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etiology of angiogenesis inhibition-related hypertension.
    Lankhorst S; Saleh L; Danser AJ; van den Meiracker AH
    Curr Opin Pharmacol; 2015 Apr; 21():7-13. PubMed ID: 25500206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.
    León-Mateos L; Mosquera J; Antón Aparicio L
    Redox Biol; 2015 Dec; 6():421-425. PubMed ID: 26386874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Antihypertensive Drugs in Neoplastic Patients.
    Rizzoni D; De Ciuceis C; Porteri E; Agabiti-Rosei C; Agabiti-Rosei E
    High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):127-132. PubMed ID: 28361339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension.
    Kruzliak P; Kovacova G; Pechanova O
    Angiogenesis; 2013 Apr; 16(2):289-95. PubMed ID: 23203441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1.
    Lankhorst S; Kappers MH; van Esch JH; Danser AH; van den Meiracker AH
    J Hypertens; 2013 Mar; 31(3):444-54; discussion 454. PubMed ID: 23221987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.
    Ferroni P; Della-Morte D; Palmirotta R; Rundek T; Guadagni F; Roselli M
    Curr Vasc Pharmacol; 2012 Jul; 10(4):479-93. PubMed ID: 22272903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?
    le Noble FAC; Mourad JJ; Levy BI; Struijker-Boudier HAJ
    Hypertension; 2023 May; 80(5):901-911. PubMed ID: 36748474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic-induced hypertension: the molecular basis of signaling network.
    Nagai A; Sado T; Naruse K; Noguchi T; Haruta S; Yoshida S; Tanase Y; Tsunemi T; Kobayashi H
    Gynecol Obstet Invest; 2012; 73(2):89-98. PubMed ID: 22222493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.
    Robinson ES; Khankin EV; Karumanchi SA; Humphreys BD
    Semin Nephrol; 2010 Nov; 30(6):591-601. PubMed ID: 21146124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.
    Dobbin SJH; Cameron AC; Petrie MC; Jones RJ; Touyz RM; Lang NN
    Heart; 2018 Dec; 104(24):1995-2002. PubMed ID: 30228246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
    Kappers MH; van Esch JH; Sleijfer S; Danser AH; van den Meiracker AH
    J Hypertens; 2009 Dec; 27(12):2297-309. PubMed ID: 19680138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Team-Based Approach to Management of Hypertension Associated with Angiogenesis Inhibitors.
    Patel S; Dushenkov A; Jungsuwadee P; Krishnaswami A; Barac A
    J Cardiovasc Transl Res; 2020 Jun; 13(3):463-477. PubMed ID: 32430701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
    Roodhart JM; Langenberg MH; Witteveen E; Voest EE
    Curr Clin Pharmacol; 2008 May; 3(2):132-43. PubMed ID: 18690886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs.
    Thanigaimani S; Kichenadasse G; Mangoni AA
    Curr Vasc Pharmacol; 2011 May; 9(3):358-80. PubMed ID: 20807189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.